Contract research organisation hVIVO plc (AIM:HVO) announced on Monday that it has signed an agreement with clinical-stage biotechnology company Inhalon Biopharma Inc to conduct a Respiratory Syncytial Virus (RSV) human challenge trial.
The Phase 2a trial will assess Inhalon's inhaled antiviral candidate, IN-002, using hVIVO's RSV Human Challenge Model. It will evaluate IN-002's safety, pharmacokinetics and antiviral activity at three dose levels.
hVIVO's FluCamp will recruit healthy volunteers for the study. The trial is expected to begin in the second half of 2026 at hVIVO's Canary Wharf facilities.
Revenue from the contract is primarily expected to be recognised in 2026.
IN-002 uses Inhalon's inhaled drug delivery platform.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA